Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387104485> ?p ?o ?g. }
- W4387104485 abstract "Background Accurate prediction of efficacy of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors is of critical importance. To address this issue, a network meta-analysis (NMA) comparing existing common measurements for curative effect of PD-1/PD-L1 monotherapy was conducted. Methods We searched PubMed, Embase, the Cochrane Library database, and relevant clinical trials to find out studies published before Feb 22, 2023 that use PD-L1 immunohistochemistry (IHC), tumor mutational burden (TMB), gene expression profiling (GEP), microsatellite instability (MSI), multiplex IHC/immunofluorescence (mIHC/IF), other immunohistochemistry and hematoxylin-eosin staining (other IHC&HE) and combined assays to determine objective response rates to anti–PD-1/PD-L1 monotherapy. Study-level data were extracted from the published studies. The primary goal of this study was to evaluate the predictive efficacy and rank these assays mainly by NMA, and the second objective was to compare them in subgroup analyses. Heterogeneity, quality assessment, and result validation were also conducted by meta-analysis. Findings 144 diagnostic index tests in 49 studies covering 5322 patients were eligible for inclusion. mIHC/IF exhibited highest sensitivity (0.76, 95% CI: 0.57-0.89), the second diagnostic odds ratio (DOR) (5.09, 95% CI: 1.35-13.90), and the second superiority index (2.86). MSI had highest specificity (0.90, 95% CI: 0.85-0.94), and DOR (6.79, 95% CI: 3.48-11.91), especially in gastrointestinal tumors. Subgroup analyses by tumor types found that mIHC/IF, and other IHC&HE demonstrated high predictive efficacy for non-small cell lung cancer (NSCLC), while PD-L1 IHC and MSI were highly efficacious in predicting the effectiveness in gastrointestinal tumors. When PD-L1 IHC was combined with TMB, the sensitivity (0.89, 95% CI: 0.82-0.94) was noticeably improved revealed by meta-analysis in all studies. Interpretation Considering statistical results of NMA and clinical applicability, mIHC/IF appeared to have superior performance in predicting response to anti PD-1/PD-L1 therapy. Combined assays could further improve the predictive efficacy. Prospective clinical trials involving a wider range of tumor types are needed to establish a definitive gold standard in future." @default.
- W4387104485 created "2023-09-28" @default.
- W4387104485 creator A5006872949 @default.
- W4387104485 creator A5021541475 @default.
- W4387104485 creator A5030398519 @default.
- W4387104485 creator A5054049388 @default.
- W4387104485 creator A5058249691 @default.
- W4387104485 date "2023-09-26" @default.
- W4387104485 modified "2023-10-14" @default.
- W4387104485 title "Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis" @default.
- W4387104485 cites W2049553585 @default.
- W4387104485 cites W2074465378 @default.
- W4387104485 cites W2299181842 @default.
- W4387104485 cites W2341726189 @default.
- W4387104485 cites W2560367415 @default.
- W4387104485 cites W2582671354 @default.
- W4387104485 cites W2594836176 @default.
- W4387104485 cites W2635951006 @default.
- W4387104485 cites W2655262992 @default.
- W4387104485 cites W2739132742 @default.
- W4387104485 cites W2763048166 @default.
- W4387104485 cites W2788797147 @default.
- W4387104485 cites W2792627271 @default.
- W4387104485 cites W2793364080 @default.
- W4387104485 cites W2796494201 @default.
- W4387104485 cites W2800160190 @default.
- W4387104485 cites W2801456259 @default.
- W4387104485 cites W2805302875 @default.
- W4387104485 cites W2884397450 @default.
- W4387104485 cites W2888172308 @default.
- W4387104485 cites W2889746019 @default.
- W4387104485 cites W2897283341 @default.
- W4387104485 cites W2897815318 @default.
- W4387104485 cites W2901131610 @default.
- W4387104485 cites W2903527992 @default.
- W4387104485 cites W2912137016 @default.
- W4387104485 cites W2913044136 @default.
- W4387104485 cites W2923110622 @default.
- W4387104485 cites W2924122631 @default.
- W4387104485 cites W2938645074 @default.
- W4387104485 cites W2954094199 @default.
- W4387104485 cites W2961686530 @default.
- W4387104485 cites W2965019135 @default.
- W4387104485 cites W2966816506 @default.
- W4387104485 cites W2970410478 @default.
- W4387104485 cites W2981696991 @default.
- W4387104485 cites W2983296614 @default.
- W4387104485 cites W3008867012 @default.
- W4387104485 cites W3010680101 @default.
- W4387104485 cites W3012256786 @default.
- W4387104485 cites W3015454783 @default.
- W4387104485 cites W3017200036 @default.
- W4387104485 cites W3023081021 @default.
- W4387104485 cites W3024881937 @default.
- W4387104485 cites W3035838036 @default.
- W4387104485 cites W3042495206 @default.
- W4387104485 cites W3083986479 @default.
- W4387104485 cites W3094376062 @default.
- W4387104485 cites W3095901982 @default.
- W4387104485 cites W3096112873 @default.
- W4387104485 cites W3104068360 @default.
- W4387104485 cites W3113132520 @default.
- W4387104485 cites W3117348379 @default.
- W4387104485 cites W3118998396 @default.
- W4387104485 cites W3128131226 @default.
- W4387104485 cites W3128938704 @default.
- W4387104485 cites W3129917327 @default.
- W4387104485 cites W3134905109 @default.
- W4387104485 cites W3149571937 @default.
- W4387104485 cites W3155675611 @default.
- W4387104485 cites W3160231856 @default.
- W4387104485 cites W3161640011 @default.
- W4387104485 cites W3173096232 @default.
- W4387104485 cites W3189025068 @default.
- W4387104485 cites W3192817154 @default.
- W4387104485 cites W3196194192 @default.
- W4387104485 cites W3199389162 @default.
- W4387104485 cites W3215340942 @default.
- W4387104485 cites W4200388746 @default.
- W4387104485 cites W4200417352 @default.
- W4387104485 cites W4225144608 @default.
- W4387104485 cites W4229443519 @default.
- W4387104485 cites W4238025061 @default.
- W4387104485 cites W4281568334 @default.
- W4387104485 cites W4281703711 @default.
- W4387104485 cites W4283030292 @default.
- W4387104485 doi "https://doi.org/10.3389/fimmu.2023.1265202" @default.
- W4387104485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37822932" @default.
- W4387104485 hasPublicationYear "2023" @default.
- W4387104485 type Work @default.
- W4387104485 citedByCount "0" @default.
- W4387104485 crossrefType "journal-article" @default.
- W4387104485 hasAuthorship W4387104485A5006872949 @default.
- W4387104485 hasAuthorship W4387104485A5021541475 @default.
- W4387104485 hasAuthorship W4387104485A5030398519 @default.
- W4387104485 hasAuthorship W4387104485A5054049388 @default.
- W4387104485 hasAuthorship W4387104485A5058249691 @default.
- W4387104485 hasBestOaLocation W43871044851 @default.
- W4387104485 hasConcept C104317684 @default.
- W4387104485 hasConcept C125473707 @default.